Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of�…

Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin thought to arise
from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed�…

This year's American Society of Clinical Oncology International Symposium devoted 2 hours
to a lively discussion of various aspects of anticancer drug discovery and development�…

The involvement of whole-chromosome aneuploidy in tumorigenesis is the subject of
debate, in large part because of the lack of insight into underlying mechanisms. Here we�…

Abstract Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ) is a receptor
tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug�…

Abstract Purpose: To describe the Food and Drug Administration review and marketing
approval considerations for bortezomib (Velcade) for the treatment of patients with mantle�…

The extent of lung regeneration following catastrophic damage and the potential role of adult
stem cells in such a process remains obscure. Sublethal infection of mice with an H1N1�…

Centrosome amplification has long been recognized as a feature of human tumours;
however, its role in tumorigenesis remains unclear. Centrosome amplification is poorly�…

Purpose: To discuss vorinostat approval for treatment of cutaneous manifestations of
advanced cutaneous T-cell lymphoma (CTCL). Experimental Design: Data from 1 single�…

Learning Objectives After completing this course, the reader will be able to: Discuss the
mechanism of action of the newly approved targeted cancer drug sunitinib. List the current�…